Canaccord Genuity Group Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $171.44 price objective on the stock. Canaccord Genuity Group’s price target points to a potential upside of 70.91% from the company’s previous close. A […]
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $171.44 price objective on the stock. Canaccord Genuity Group’s price target points to a potential upside of 70.91% from the company’s previous close. A […]
